key: cord-1016892-ktdqwxjn
authors: Tsao, Shih-Ming; Wang, Jann-Yuan; Li, Chien-Feng; Hsieh, Ming-Chang; Wang, Yao-Tung; Chan, Kuei-Chuan; Pan, Hui-Hsien; Lee, Yuan-Ti; Huang, Yi-Wen
title: Successful Treatment of a Critical COVID-19 Patient with Tocilizumab
date: 2020-10-24
journal: J Formos Med Assoc
DOI: 10.1016/j.jfma.2020.10.021
sha: d466cbe558e3753cd42cdb7ce8c321cb56bc3d4d
doc_id: 1016892
cord_uid: ktdqwxjn

nan

1 Dear editor, Interleukin (IL)-6 has been suggested as one critical mediator in acute respiratory distress syndrome (ARDS) due to severe COVID-19. 1 Given that antiviral agents with a confirmed therapeutic effect for COVID-19 remains lacking, 2 

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

Effective treatment of severe COVID-19 patients with tocilizumab